Search
Results: 8
Impact of achievement and change in achievement of lifestyle recommendations in middle-age on risk of the most common potentially preventable cancers.
Juliet A Usher-Smith, Christel Häggström, Patrik Wennberg, Kristina Lindvall, Jean Strelitz, Stephen J Sharp, Simon J Griffin
Jul 07, 2021
Circulating Selenium and Prostate Cancer Risk
James Yarmolinsky, Carolina Bonilla, Philip C Haycock, Ryan JQ Langdon, Luca A Lotta, Claudia Langenberg, Caroline L Relton, Sarah J Lewis, David M Evans, PRACTICAL Consortium, George Davey Smith, Richard M Martin
Sep 18, 2018
In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), selenium supplementation (causing a median 114 μg/L increase in circulating selenium) did not lower overall prostate cancer risk, but increased risk of high-grade...
An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases
Shakira Milton, Jennifer McIntosh, Finlay Macrae, Patty Chondros, Lyndal Trevena, Mark Jenkins, Fiona M Walter, Natalie Taylor, Lucy Boyd, Sibel Saya, Napin Karnchanachari, Kitty Novy, Carmody Forbes, Javiera Martinez Gutierrez, Kate Broun, Sara Whitburn, Sarah McGill, George Fishman, Julie Marker, Max Shub, Jon Emery
Sep 05, 2021
BACKGROUND: Australian guidelines recommend that all people aged 50-70 years old actively consider taking daily low-dose aspirin (100-300 mg per day) for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC). Despite...
Aspirin bowel cancer cancer prevention Chemoprevention colorectal cancer decision aid General Practice Guideline implementation Informed decision making PREVENTIVE MEDICINE PRIMARY CARE Aged Aspirin Chronic Disease Colorectal Neoplasms Decision Support Techniques Humans Middle Aged Randomized Controlled Trials as Topic Victoria
Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus
Nicholas Swart, Roberta Maroni, Beth Muldrew, Peter Sasieni, Rebecca C Fitzgerald, Stephen Morris, BEST3 Consortium
Aug 19, 2021
BACKGROUND: Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma. Randomised...
Current opportunities to catalyze research in nutrition and cancer prevention – an interdisciplinary perspective
The Cancer Research UK - Ludwig Cancer Research Nutrition and Cancer Prevention Collaborative Group
Jul 31, 2019
Cancer Research UK and Ludwig Cancer Research convened an inaugural international Cancer Prevention and Nutrition Conference in London on December 3–4, 2018. Much of the discussion focused on the need for systematic...
cancer prevention Developmental origins Diet EPIDEMIOLOGY epigenetics interdisciplinary metabolism Nutrition obesity physical activity Public Health Biomedical Research Body Weight Congresses as Topic Diet Exercise food Humans Interdisciplinary Communication Interdisciplinary Research Neoplasms Nutrition Therapy Nutritional Status obesity Risk Factors United Kingdom
Economic evaluation of Cytosponge®-trefoil factor 3 for Barrett esophagus
Nicholas Swart, Roberta Maroni, Beth Muldrew, Peter Sasieni, Rebecca C Fitzgerald, Stephen Morris
Aug 02, 2021
Background
Esophageal adenocarcinoma has a very poor prognosis unless detected early. The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a precursor of esophageal adenocarcinoma....
Published by: EClinicalMedicine
An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases
Shakira Milton, Jennifer McIntosh, Finlay Macrae, Patty Chondros, Lyndal Trevena, Mark Jenkins, Fiona M. Walter, Natalie Taylor, Lucy Boyd, Sibel Saya, Napin Karnchanachari, Kitty Novy, Carmody Forbes, Javiera Martinez Gutierrez, Kate Broun, Sara Whitburn, Sarah McGill, George Fishman, Julie Marker, Max Shub, Jon Emery
Jul 28, 2021
Abstract: Background: Australian guidelines recommend that all people aged 50–70 years old actively consider taking daily low-dose aspirin (100–300 mg per day) for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC)....
An RCT of a decision aid to support informed choices about taking aspirin to prevent colorectal cancer and other chronic diseases
Shakira Milton, Jennifer McIntosh, Finlay Macrae, Patty Chondros, Lyndal Trevena, Mark Jenkins, Fiona M Walter, Natalie Taylor, Lucy Boyd, Sibel Saya, Napin Karnchanachari, Kitty Novy, Carmody Forbes, Javiera Martinez Gutierrez, Kate Broun, Sara Whitburn, Sarah McGill, George Fishman, Julie Marker, Max Shub, Jon Emery
Aug 16, 2021
Background
Australian guidelines recommend that all people aged 50-70 years old actively consider taking daily low-dose aspirin (100-300 mg per day) for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC)....
Chemoprevention Aspirin colorectal cancer General Practice PREVENTIVE MEDICINE PRIMARY CARE bowel cancer cancer prevention Informed decision making Guideline implementation decision aid Humans Colorectal Neoplasms Chronic Disease Aspirin Decision Support Techniques Aged Middle Aged Victoria Randomized Controlled Trials as Topic
Published by: Trials